Amplification of the MYCN oncogene contributes to the malignant progression of human neuroblastomas, but the mechanisms have remained unclear. We have previously demonstrated that N-Myc facilitates angiogenesis by downregulating an angiogenesis inhibitor identified as the inhibin bA homodimer activin A. Here, we have sought to define the molecular, biological and clinical consequences of activin A expression in human neuroblastoma. We report that enhanced activin A expression suppresses proliferation and colony formation of human neuroblastoma cells with amplified MYCN in vitro; that it inhibits neuroblastoma growth and angiogenesis in vivo; that it is highly expressed in differentiated, but not undifferentiated human neuroblastomas; and that it correlates with favourable outcome of neuroblastoma patients. Our results indicate that high activin A expression plays an important beneficial role in human neuroblastoma.
Introduction
Neuroblastoma is a pediatric malignancy derived from immature sympathetic precursor cells of the neural crest. It can be classified into three groups addressing their clinical and biological properties: the first group is characterized by hyperdiploid karyotype, normal chromosomes, low stage and a favourable prognosis, the second by near-diploid or tetraploid karyotype, structural chromosomal anomalies, normal MYCN and an intermediate, highly variable prognosis and the third group by diploidy, chromosome 1p deletion, high TrkB expression, amplified MYCN, and poor prognosis (Brodeur, 2003) . Despite aggressive multimodal therapy, survival rates have remained in the range of 60 or 25% for patients of all disease stages or of most the advanced stage 4 (of 4), respectively (Brodeur, 2003) .
Although the mechanisms leading to the progression of human neuroblastoma have remained unclear, amplification of the MYCN oncogene appears to contribute significantly (Westermann and Schwab, 2002) . We have previously demonstrated that MYCN overexpression stimulates angiogenesis by the concomitant downregulation of three angiogenesis inhibitors (Fotsis et al., 1999) , one of which was identified as activin A (Breit et al., 2000) . Within the large superfamily of transforming growth factor (TGF)-b members, activin A is a member of the inhibin/activin family of growth modulators (Mather et al., 1997; Chen et al., 2002) . Activin A is a homodimeric M r E25 kDa protein composed of two inhibin bA chains whereas other members of the inhibin/activin family including activin B, activin AB, inhibin A or inhibin B are composed of inhibin-bB homodimers, inhibin bA/inhibin bB heterodimers, inhibin-a/inhibin bA heterodimers or inhibin-a/ inhibin-bB heterodimers, respectively. Activin A is evolutionary conserved and controls various functions (Mather et al., 1997) .
We have previously demonstrated that enhanced MYCN expression downregulates activin A and that it inhibits angiogenesis (Breit et al., 2000) , but we did not evaluate the direct consequences of activin A on neuroblastoma growth and angiogenesis. The present study was designed to address these questions. We selected a human neuroblastoma cell line (Kelly) with amplified MYCN and transfected the cells with a vector containing human inhibin bA cDNA or with the empty vector as a control. Using this cellular model, we sought to define the biological and clinical consequences of enhanced activin A expression in human neuroblastomas.
Results
We have previously demonstrated that over-expression of MYCN in human neuroblastoma cells results in the downregulation of an angiogenesis inhibitor identified as activin A (Breit et al., 2000) , suggesting a beneficial role for activin A in neuroblastoma biology. To verify this hypothesis and to demonstrate directly the potentially favourable properties of activin A in neuroblastoma, we selected a highly malignant human neuroblastoma cell line (Kelly) with amplified MYCN (Schweigerer et al., 1990) and no detectable expression of either member of the inhibin/activin family (data not shown). We transfected this cell line with a vector containing a geneticin resistance gene and human inhibin bA cDNA so as to establish high activin A expression. In a parallel experiment, we transfected Kelly cells with the empty vector and used these and the native, untransfected cells as controls. Kelly cells transfected with the inhibin bA cDNA were selected in the presence of geneticin and gave rise to a cell line (termed KT3), which expressed inhibin bA mRNA and secreted immunoreactive (1 ng/mg total protein as determined by ELISA) and bioactive activin A (data not shown) into the medium. In contrast, the control cell line (named KT2) expressed neither inhibin bA nor immunoreactive activin A (Figure 1a and b) .
To determine the character and quality of the potential biological consequences of enhanced activin A expression, we compared gene expression profiles of KT3, KT2 and native Kelly cells using Affymetrix 'cancer gene' chips with oligonucleotides representing about 1600 cancer-related genes. As demonstrated in Table 1 , activin A modulated expression of various molecules. Downregulation was most prominent for insulin-like growth factor-II (IGF-II), which has been implicated in neuroblastoma progression. Upregulation was strongest in the case of vasoactive intestinal protein (VIP), BIGH3 and LMO4, which have been demonstrated to inhibit neuroblastoma growth (not shown). All data were confirmed by RT-PCR (Figure 1c ). These properties suggested that the activin A-mediated transcriptional program would eventually result in the inhibition of neuroblastoma growth and/or progression.
In fact, growth rates of activin A-expressing (KT3) cells were considerably attenuated when compared to those of KT2 or native Kelly cells (Figure 2a) , and this effect could be antagonized by recombinant follistatin (data not shown). Thus, activin A appeared to suppress the malignant potential of neuroblastoma cells. Since the ability to grow anchorage-independent at clonal density and in colonies is a feature of malignant cells, we compared the abilities of the neuroblastoma cells to grow in soft agar. As demonstrated in Figure 2b , native Kelly cells and the control transfectants (KT2), but not the activin A-producing neuroblastoma cells (KT3) were able to form colonies in soft agar, indicating that activin A suppresses the malignant phenotype of human neuroblastoma cells. This assumption is supported by data obtained independently with the human neuroblastoma cell line WAC2 (Schweigerer et al., 1990 and T. Fotsis, personal communication) .
In order to investigate the consequences of enhanced activin A expression for neuroblastoma growth in vivo, we compared the abilities of the control cells with those of KT3 cells to grow in immune-deficient nude mice. Native Kelly cells or KT2 cells formed measurable tumours 14 (mean; 95% confidence interval 13-15 days) or 17 (14-20) days, respectively, after subcutaneous injection. In contrast, KT3 cells formed measurable tumours only with significant delay, that is, 30 (23-37) days after tumour cell injection (Po0.001) (Figure 3a) . Mice carrying tumours derived from KT3 cells lived significantly longer (mean 4473 days) (Po0.001) from inoculation of tumour cells to the primary end point (i.e. when tumours had expanded to 10% or more of the body weight) than mice carrying tumours derived from KT2 or native Kelly cells (mean 2475 days or 2774 days, respectively) ( Figure 3b ). In addition, KT3 cellderived tumours appeared considerable paler than those derived from the control cells (Figure 3c ), suggesting activin A-mediated suppression of tumour angiogenesis.
To determine whether activin A-mediated suppression of neuroblastoma growth in vivo resulted from the inhibition of neuroblastoma cell proliferation and/or tumour angiogenesis, we compared experimental neuroblastomas by immunohistochemistry using antibodies directed against the proliferation marker Ki67 or the blood vessel marker CD-31, respectively. Tumours derived from control (native Kelly or KT2) cells were Figure 4a ). Tumours derived from the controls (native Kelly or KT2 cells) contained 25.074.5 or 26.175.9 microvessels per visual field, respectively, whereas those derived from KT3 cells contained 18.670.7 microvessels per field. Vessel densities in KT3-derived tumours were lower than in the combined controls (25.573.4), but the difference did not reach statistical significance (P ¼ 0.214, Figure 4b ). Thus, activin A suppresses neuroblastoma growth and, apparently, neuroblastoma angiogenesis. Our experimental data suggested that activin A could suppress neuroblastoma progression clinically. To evaluate this hypothesis, we first excluded expression of inhibin bB and inhibin a (not shown) and subsequently determined expression of inhibin bA in 78 human neuroblastoma samples using semiquantitative RT-PCR and inhibin bA-specific primers. While inhibin bA expression was low or undetectable in most samples, it was high in the remainders (range 0-1.36 density units (du); quartiles 0.01-0.05-0.14 du; 80th percentile 0.22 du). Inhibin bA expression did not differ significantly in neuroblastomas with regard to sex, age or stage (not shown). In contrast, neuroblastomas with MYCN amplification showed a significantly lower inhibin bA expression (n ¼ 17; quartiles 0.00-0.03-0.06 du) than neuroblastomas without MYCN amplification (n ¼ 61; quartiles 0.01-0.05-0.21 du; P ¼ 0.042). When patients were categorized for high (group 1, n ¼ 15) or low (group 2, n ¼ 63) inhibin bA expression, both groups included male and female patients of all ages and stages, with no significant differences detectable. Only one tumour (6.7%) in group 1 of patients contained MYCN amplification, as opposed to 16 tumours in group 2 of patients (25.4%). This difference was also not significant.
We investigated whether inhibin bA expression would predict the outcome of our patients. As shown in Figure 5a , high inhibin bA expression predicted an excellent outcome (group 1, EFS 92.976.9%) as Figure 5b ). Since we did neither detect inhibin bB nor inhibin a, our data suggest that inhibin bA expression results in production of activin A. These data are in line with preliminary results demonstrating elevated activin A levels in neuroblastoma patients, but not healthy children.
To further validate these data, we studied expression of activin A by immunohistochemistry using paraffin sections of human neuroblastomas and an antibody which detects both mature inhibin bA and its precursor protein but not related activin or inhibin molecules. In undifferentiated, cell-dense neuroblastomas we were unable to detect activin A (Figure 5c, left) . In contrast, Mice were killed according to institutional guidelines, that is, once tumours had reached 10% of total body weight or a volume beyond 2.5 cm 3 (primary endpoint) Each data point represents survival of a single animal shown in (a). Survival ( ¼ time from inoculation to the primary end point) was significantly increased in the KT3 group as compared to parental cell line and control (Po0.001). (c) Representative tumours obtained after injection of K, KT2 or KT3 cells were excised once they had reached 10% of body weight and photographed. An asterisk marks statistical significance Activin A and neuroblastoma A Schramm et al activin A was readily detected in neuroblastomas with a differentiated phenotype including large perikarya, pale nuclei with nucleoli, polarity and axon formation (Figure 5c , middle and right). The activin A signal was preferentially observed in perikarya (arrows) and nerve fibers. We also detected inhibin bA in the tunica intima and media of blood vessels (data not shown), suggesting a function for both neuroblastoma cells and blood vessels.
In conclusion, our results demonstrate that activin A suppresses neuroblastoma growth and potentially angiogenesis and they suggest that these mechanisms are of clinical benefit. Finally, inhibin bA expression may serve as an independent indicator to better define the prognosis of patients of class 2 neuroblastomas.
Discussion
Activin A is already present in the early embryo where it participates among other molecules (including TGF-b-related molecules and nodal) in mesoderm induction (Altaba and Melton, 1989) . During later development, it contributes to various inductive events generally leading to differentiation and a concomitant loss of proliferation (Mather et al., 1997) . Here, we have demonstrated that activin A inhibits proliferation of human neuroblastoma cells. Our findings appear to be in contrast to those of other groups who have demonstrated that activin A supports proliferation and inhibits differentiation of nontransformed neuronal cells (Iwahori et al., 1997; Wu et al., 1999) . These apparent discrepancies may be explained by the different embryonic origin of the cells and their differentiation status. That activin A inhibits neuroblastoma proliferation has been confirmed recently by another group (Cinatl et al., 2002) . It is possible that this occurs by suppression of an autocrine IGF-II-involving pathway. Alternatively, activin A may mediate these effects indirectly through molecules implicated in the modulation of cell proliferation and differentiation. This possibility is supported by activin A-induced upregulation of the homeobox or homeoboxrelated molecules Hox5.4 or LMO4 (Table 1) . Both molecules are implicated in cell and tissue differentiation (Hermanson et al., 1999; Giusti et al., 2000; Visvader et al., 2001) . For example, LMO4 participates in the differentiation of progenitor cells of motoneurons, of the cranial neural crest and of Schwann cells and induces regression of mammary tissue (Hermanson et al., 1999; Visvader et al., 2001) . That activin A suppresses neuroblastoma growth and angiogenesis is supported by the clinical data presented in Figure 5 . Here, we have demonstrated for the first time that high expression of the activin A-encoding gene inhibin bA is associated with favourable outcome of neuroblastoma patients and vice versa. This behaviour is found in, but not exclusive to, MYCN-amplified neuroblastomas (Figure 5 ), suggesting that factors other than MYCN regulate inhibin bA and/or activin A expression. In fact, this assumption is supported by various recent studies (Andreasson and Worley, 1995; Hu¨bner and Werner, 1996; Tuuri et al., 1996; Woodruff et al., 1997; Cinatl et al., 2002) .
Clinical and biological data support the existence of three groups of patients with neuroblastomas (Brodeur, 2003) . Whereas the 5-year survival rates of patients classified into groups 1 and 3 can be accurately estimated, those of stage 2 patients vary widely, that is, between 25 and 50%. The data presented here demonstrate that inhibin bA expression may serve as a novel molecular marker, which can accurately specify survival probabilities within group 2 patients. Thereby, inhibin bA determination may be helpful for therapeutic decisions.
Materials and methods

Materials
All chemicals were obtained either from Sigma or Merck (Munich or Darmstadt, Germany). Inhibin bA-cDNA in pBluescript KS þ was a gift from Dr R Hochpo¨hler (EMBL, Heidelberg).
Cloning of inhibin 1 bA and cell transfection
Inhibin bA-cDNA was inserted into the NotI/XhoI sites of pcDNA 3.1. (Invitrogen, Groningen, The Netherlands). Sequence analysis of the cloned DNA fragment revealed the identity with the published inhibin bA sequence (GenBank entry NM_002192). Transfection of Kelly and embryonic kidney cells was achieved using 'Superfect Transfection Reagent' (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. Briefly, 2 Â 10 7 cells were incubated with 'Superfect' reagent and 10 mg of vector DNA containing the human inhibin bA-cDNA. Plasmid uptake was selected for by adding G418 (10 mg/ml) to the media. Transfected cells were isolated by ring cloning.
RT-PCR
Inhibin bA-or glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-cDNA were amplified as described previously (Breit et al., 2000) . Primer sets were used alone or together in a duplex-RT-PCR reaction.
For semiquantitative analysis of neuroblastoma specimens, inhbin bA/GAPDH duplex RT-PCR products of neuroblastoma RNA were separated on 1.5% agarose gels. Scanned images were analysed using 'NIH image for MacIntosh'. Inhbin bA expression was defined according to the inhibin bA/ GAPDH band intensity ratio as arbitrary du. Lanes without detectable GAPDH signals were excluded. Primers used for amplification of genes were as described (Breit et al., 2000 
Western blotting
Cells were extracted by exposure to RIPA lysis buffer (50 mM Tris-HCl containing NaCl (300 mM), NP-40 (1%), deoxycholate (0.5%), sodium dodecylsulfate (0.1%) and 'complete' protease inhibitor (Roche Diagnostics, Mannheim, Germany) (pH 8.0)). Protein concentration was determined using DC Protein assays (Bio-Rad, Munich, Germany). Extracts (20 mg of protein/lane) were separated by 10% SDS-PAGE under reducing conditions and transferred onto nitrocellulose membranes (Schleicher and Schu¨ll, Dassel, Germany) previously exposed for 1 h at 201C with non-fat dried milk (3%) in phosphate-buffered saline (PBS). Membranes were incubated overnight with a 1 : 1000 dilution of monoclonal activin Aspecific antibodies (Serotec, Du¨sseldorf, Germany), washed three times with PBS containing Tween-20 (0.4%), and exposed to secondary antibodies coupled to horseradish peroxidase. Activin A-immunoreactivity was visualized using ECL chemiluminescence (Amersham Pharmacia, Piscataway, NJ, USA).
Microarray analyses
Total RNA was prepared from neuroblastoma cells during logarithmic growth phase using TRIZOL (Life Technologies, Rockville, MA, USA), according to the standard protocols (Chomczynski, 1993) . RNA was cleaned and DNA was removed by using RNeasy columns (QIAGEN, Hilden, Germany), according to the manufacturer's suggestions. Labelling of cRNA and hybridization of labelled probes with the Human Cancer G110 Gene Chip s was carried out according to the manufacturer's recommendations (Affymetrix, Santa Clara, CA, USA). Data readout and global scaling was essentially as described (Wai et al., 2002) . Data analysis was performed with 'Microarray Analysis Suite 5.0' and 'Data Mining Tool 3.0' (Affymetrix, Santa Clara, CA, USA). The criteria for a transcript to be called differentially expressed between Kelly and empty-vector control or activin A-expressing Kelly cells were: (1) signal>400 and call ¼ 'P' (present) in at least one sample; (2) DiffCall ! ¼ 'NC' no change); (3) FC (fold change) >2.5. Signals o100 were set to 100.
Cell culture and bioassays
All cells were cultured in RPMI 1640 containing 10% foetal calf serum and penicillin and streptomycin/(100 U/ml) (Schweigerer et al., 1990; Fotsis et al., 1997 Fotsis et al., , 1999 Ro¨ssler et al., 1999) . Transfected neuroblastoma cells received additionally G418 (10 mg/ml twice a week) for continuous selection. Cell proliferation was quantified as previously reported (Schweigerer et al., 1987) .
Animal experiments
Experimental neuroblastomas were established as described (Schweigerer et al., 1990) . Palpable masses were defined as tumours. Subsequently, tumour size, body weight, and general status of the animals were recorded every 2 or 3 days. Perpendicular tumour volume was calculated from the formula: (longest diameter) Â (shortest diameter) 2 Â 0.5. Mice were killed at times regulated by local institutional guidelines, that is, once tumours had reached sizes of approximately 2.5 cm 3 or 10% of the body weight.
Immunohistochemistry
Tumours generated from KT3, KT2 or native Kelly cells were excised from killed animals, fixed in formalin (4%) over night, embedded in paraffin, sectioned and mounted on glass slides. Sections were deparaffinized through graded xylene and alcohol washes and treated for 10 min with proteinase K (DAKO, Hamburg, Germany) prior to immunohistochemistry. For Ki67 or CD31 staining, we incubated sections with monoclonal mouse anti-human Ki67 antibodies (clone MiB-1, DAKO, Hamburg, Germany, 1 : 100) for 1 h at room temperature or with monoclonal rat anti-mouse PECAM-1 antibodies (BD Pharmingen, San Jose, CA, 1 : 50) overnight at 41C. Glass slides were washed with PBS and antibody binding was determined with Fuchsin (DAKO, Hamburg, Germany) as a substrate. For tumour morphology, sections were also stained with hematoxylin-eosin. For analysis of human specimen, paraffin sections of human neuroblastomas (n ¼ 7) were deparaffinized with rotihistol (Carl Roth, Karlsruhe, Germany). Endogenous peroxidase was blocked with 0.3% hydrogen peroxide in methanol for 30 min. Sections were then incubated for 5 min in PBS containing 0.05% Tween-20, washed two times in PBS and blocked with 1%BSA in PBS for 20 min. Primary antibody, mouse-anti-human inhibin bA (Serotec, Oxford, UK), was diluted 1 : 20 in PBS and incubated for 1 h. The secondary antibody was peroxidase-conjugated goat-anti-mouse IgG, diluted 1 : 200 (Sigma, St Louis, USA). Diaminobenzidine (Sigma) was used as chromogen. Sections were counter-stained with nuclear fast red.
Patients and specimens
The local ethics committee approved the study. Neuroblastoma specimens, clinical data and written informed consent of the patients' guardians were obtained within the treatment studies NB 85 and NB 90 of the German Society for Paediatric Oncology and Haematology (GPOH). From a bank of neuroblastoma specimens, we randomly chose 95 samples (collected between 1987 and 1998) , and excluded post hoc those without sufficient mRNA quality. The remaining 78 patients (40 male, 33 female, five unspecified) were aged between 0 and 116 months (median, 19 months). According to the International Neuroblastoma Staging System (INSS (Brodeur et al., 1993) , 17 patients had stage 1, 11 stage 2, 17 stage 3, 25 stage 4, and eight stage 4S tumours, respectively. In toal, 17 neuroblastomas (22%) showed MYCN amplification. During follow-up time (minimum and maximum 1 and 96 months, respectively, median 27 months), 26 major events occurred, resulting in a 5 years event-free survival rate (EFS) of 57.776.8% (standard error). Investigators were blind to all clinical data until mRNA analysis was completed.
Statistical analyses
For experimental animals, we calculated and compared tumour take (from inoculation to tumour formation) and survival times (from tumour inoculation to killing). Microvessel densities and the percentage of Ki67-positive cells in animal tumours were tested using Student's t-test for independent groups. All statistical tests were two-sided, and a P-value of 0.05 was considered statistically significant.
For patients, MYCN amplification was defined as X4 copies/haploid genome. High inhibin bA expression was defined as a value above the 80th percentile of all inhibin bA expression levels (according to Cantero et al., 1999) . The Mann-Whitney U test was used to test for differences in inhibin bA expression levels between neuroblastomas categorized by patients' sex, age, tumour stage and MYCN amplification. Fisher's exact test was used to test for associations between high inhibin bA expression and clinical parameters. The EFS was calculated according to the KaplanMeier method as the time from diagnosis to the first major event (1st relapse or 1st progression of disease) or, in censored cases, to the last follow-up. Early censoring was mostly due to a late entry date, as compared to the end of the study, but in two cases due to iatrogenic death. Differences in the survival distributions were compared using the log-rank test.
Abbreviations du, density units; EFS, cumulative event-free survival rate after 5 years; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IGF, insulin-like growth factor; INHBA, inhibin bA; NB, neuroblastoma; TGF, transforming growth factor; TrkA/B, tyrosine receptor kinase A or B, respectively; VIP, vasoactive intestinal peptide.
